NCT05737979

Modified Rekovelle and Menopur Combination Protocol to Avoid Monitoring Before Day 10 of Stimulation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 772 (actual)
• Sponsor: Clinique Ovo · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: —

Summary

Follitropin delta (Rekovelle) algorithm established by Ferring provides personalized gonadotrophin doses based on each patient's weight and AMH. As a result, risks of stimulation failure or ovarian hyperstimulation syndrome (OHSS) during an in vitro fertilization (IVF) cycle are minimized. As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.

Detailed description

The purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of Rekovelle and Menopur duting an antagonist IVF cycle. Based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.

Conditions

• Infertility
• IVF

Interventions

Type	Name	Description
OTHER	Study chart review	Evaluation of the IVF cycle using the prescribed medication

Timeline

• Start date: 2023-01-27
• Primary completion: 2023-11-30
• Completion: 2024-01-27
• First posted: 2023-02-21
• Last updated: 2024-02-20

Locations

1 site across 1 country: Canada